SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Assertio Holdings, Inc. (ASRT) (CIK 0001808665) (ASRT) — Apr 14, 2020

Assertio Holdings, Inc. (ASRT) (CIK 0001808665)
Date: April 14, 2020 · CIK: 0001808665 · Accession: 0000000000-20-003225

AI Filing Summary & Sentiment

File numbers found in text: 333-237599

Date
April 14, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Assertio Holdings, Inc. (ASRT) (CIK 0001808665)

Letter

April 14, 2020 Arthur J. Higgins President and Chief Executive Officer Assertio Holdings, Inc. 100 South Sanders Rd., Suite 300 Lake Forest, IL 60045 Re:Assertio Holdings, Inc. Registration Statement on Form S-4 Filed April 8, 2020 File No. 333-237599 Dear Mr. Higgins: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Todd J. Trattner, Esq.

Show Raw Text
April 14, 2020
Arthur J. Higgins
President and Chief Executive Officer
Assertio Holdings, Inc.
100 South Sanders Rd., Suite 300
Lake Forest, IL 60045
Re:Assertio Holdings, Inc.
Registration Statement on Form S-4
Filed April 8, 2020
File No. 333-237599
Dear Mr. Higgins:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Todd J. Trattner, Esq.